The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Updates in amyloidosis at ASH 2020
Jason Valent, MD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, highlights the exciting new findings in the amyloidosis field presented at ASH 2020, focusing on updates from the ANDROMEDA study (NCT03201965). This trial aimed to evaluate the safety and efficacy of cyclophosphamide-bortezomib-dexamethasone (CyBorD), with or without daratumumab, in newly diagnosed systemic light-chain (AL) amyloidosis. The results of the study favor the combined CyBorD and daratumumab treatment, showing improvement in both quality of life and progression-free survival. Current studies are aiming to evaluate the safety profile of this line of therapy with the addition of CAEL-101, an amyloid deposit-targeting monoclonal antibody, to further improve outcomes in AL amyloidosis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Teaching and speaking: Celgene corporation, Takeda pharmaceuticals, Amgen corporation
